Low doses in hormone therapy of the menopausal period;Niskie dawki w terapii hormonalnej okresu menopauzy

Przeglad Menopauzalny

Volumn 5, Issue 4, 2006, Pages 223-227

  Pertyński, Tomasz ^a   Stachowiak, Grzegorz ^a  

^a POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Hormone therapy; Low doses; Menopause

Indexed keywords

ESTROGEN; GESTAGEN; SEX HORMONE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EFFICACY; ENDOMETRIUM; FEMALE; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MENOPAUSAL SYNDROME; UNSPECIFIED SIDE EFFECT;

EID: 33750565863     PISSN: 16438876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ringel M. Targeting women's health preferences. Med Manag Netw 1998; 6: 1-5.
2. Weinstein L, Bewtra C, Gallagher JC. Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient. Am J Obstet Gynecol 1990; 162: 1534-39.
3. van der Weijer PMH, Bartensen R, Kenemans P. Women's expectations and acceptance of cyclic induced HRT bleeds. Maturitas 1998; 30: 257-63.
4. Ferenczy A, Gelfand MM, van de Weijer PM, et al. Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17 beta-estradiol combined with sequential 5-20 mg dydrogesterone. Climacteric 2002; 5: 26-35.
5. Notelovitz M, Lenihan JP, McDermott M, et al. Initial 17beta-estrdiol dose for treating vasomotor symptoms. Obstet Gynecol 2000; 95: 726-31.
6. Stevenson JC. Optimising delivery systems for HRT. Maturitas 1999; 33 Suppl. 1: 31-8.
7. Sharp CA, Evans SF, Risteli L, et al. Effects of low- and conventional-dose transcutaneous HRT over 2 years on bone mineralism in younger and older postmenopausal women. Eur J Clin Invest 1996; 26: 763-71.
8. Evans SF, Davie M. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at postmenopausal ages. Clin Endocrinol (Oxf) 1996; 44: 79-84.
9. Mizunuma H, Okano H, Soda M, et al. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/ progestin therapy: a 2-year prospective study. Maturitas 1997; 27: 69-76.
10. Moyer DL, Felix JC. The effects of progesterone and progestins on endometrial proliferation. Contraception 1998; 57: 399-403.
11. Gambacciani M, Spielmann D, Genazzani AR. Efficacy of climacteric symptoms of a continuous combined regimen of 1 mg 17beta-estradiol and trimegestone versus two regimens combining 1 or 2 mg 17beta-estradiol and norethisterone acetate. Gynecol Endocrinol 2005; 21: 65-73.
12. Kurman RJ, Felix JC, Archer DF, et al. Norethindrone acetate and estradiol-induced endometrial hyperplasia. Obstet Gynecol 2000; 96: 373-79.
13. Huber JC, Campagnoli C, Druckmann R, et al. Recommendations for estrogen and progestin replacement in the climacteric and postmenopause. European Progestin Club. Maturitas 1999; 33: 197-209.
14. Sturdee DW. The importance of patient education in improving compliance. Climacteric 2000; 3 Suppl. 3: 9-13.
15. Sturdee DW. How should we give progestogen? Climacteric 2000; 3: 153-54.
16. Genazzani AD. Which form of HRT should we choose? Clin Endocrinol (Oxf) 1998; 48: 683.
17. Schindler AE, Campagnoli C, Druckmann R, et al. Aspects of progestin activity on the breast. European Progestin Club. Maturitas 1998; 29: 61-65.
18. Godsland IF, Stevenson JC. Postmenopausal hormone replacement therapy and insulin metabolism: effects on route of administration and implications for heart disease and diabetes risk. Br J Clin Pract Suppl 1996; 86: 1-5.
19. Gruber DM, Huber JC. Conjugated estrogens - the natural SERMs. Gynecol Endocrinol 1999; 13 Suppl. 6: 9-12.
20. Rekomendacje PTG w sprawie stosowania HRT. Prz Menopauz 2004; 4: 6-9.
21. Rekomendacje PTG w sprawie stosowania HRT po badaniach WHI i Million Women Study. Prz Menopauz 2003; 5: 8-9.
22. Kenemans P, Bosman A. Breast cancer and post-menopausal hormone therapy. Best Pract Res Clin Endocrinol 2003; 17: 123-37.
23. Hesch RD, Kenemans P. Hormonal prevention of breast cancer: proposal for a change in paradigm. Br J Obstet Gynaecol 1999; 106: 1006-18.
24. Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocrin Rev 2000; 21: 40-54.
25. Kandouz M, Lombet A, Perrot JY, et al. Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells. J Steroid Biochem Mol Biol 1999; 69: 463-71.
26. Druckmann R. Progestins and their effect on breast. Maturitas 2003; 46 Suppl. 1: 59-69.
27. Harlap S. The benefits and risk of hormone replacement therapy: an epidemiologic overview. Am J Obstet Gynecol 1992; 166: 1986-92.
28. Grady D, Gebretsadlk T, Kerlikowske K, et al. Hormone replacement therapy and endometrial risk: a meta-analysis. Obstet Gynecol 1995; 85: 304-13.
29. Stevenson JC, Rioux JE, Komer L, et al. 1 and 2 mg 17beta-estradiol with sequential dydrogesterone hale similar effects on the serum lipid profile of postmenopausal women. Climacteric 2005; 8: 352-9.